[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100236426":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":17,"locations":7,"responsibleParty":22,"collaborators":7,"id":26,"slug":27,"hasResults":28,"nctId":29,"briefTitle":30,"officialTitle":31,"acronym":7,"eligibilityCriteria":32,"healthyVolunteers":28,"sex":33,"minAge":34,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":35,"phases":7,"briefSummary":36,"conditions":37,"keywords":39,"overallStatus":41,"whyStopped":7,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":46,"locationsCount":7},{"fullName":5,"class":6},"Medical University of Lodz","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"BIOLOGICAL","OMS721","Human IgG4 MASP-2 Monoclonal Antibody",[14],{"name":15,"affiliation":5,"role":16},"Michal Nowicki, MD, PhD","PRINCIPAL_INVESTIGATOR",[18],{"name":15,"role":19,"phone":20,"phoneExt":7,"email":21},"CONTACT","+48 (42) 201 4400","nefro@wp.pl",{"type":23,"investigatorFullName":24,"investigatorTitle":25,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"SPONSOR_INVESTIGATOR","Michal Nowicki","Professor","100236426","oms721-compassionate-use-in-patients-with-thrombotic-microangiopathy-100236426",false,"NCT02355782","OMS721 Compassionate Use in Patients With Thrombotic Microangiopathy","Provision of OMS721 to Patients With Thrombotic Microangiopathy Under Compassionate Use","Inclusion Criteria:\n\n* Have a diagnosis of thrombotic microangiopathy related to aHUS, TTP or stem cell transplant.\n* Have completed treatment in clinical trial OMS721-TMA-001.\n* Investigator determined that continued treatment with OMS721 could be beneficial.\n* Aged 18 years or older.\n\nExclusion Criteria:\n\n* Hypersensitivity to OMS721 or any excipients.\n* Have a serious medical condition that increases the risk of OMS721 treatment to the patient.","ALL","18 Years","EXPANDED_ACCESS","The purpose of this compassionate use study, for two patients with thrombotic microangiopathy, is to provide expanded access to patients who have participated in the clinical trial OMS721-TMA-001 and in whom improvement in their disease markers was observed while on treatment or to patients who could otherwise benefit from the treatment. This is a treatment protocol; not a research protocol.Therefore, only patients in study OMS721-TMA-001 deemed eligible by the investigator may participate.",[38],"Thrombotic Microangiopathy",[40],"TMA, aHUS, TTP, stem cell transplant-associated TMA","AVAILABLE","2015-04-14",{"date":44,"type":45},"2015-04-15","ESTIMATED",{"name":24,"class":6}]